This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
February 21, 2017 – Clinical data from the Phase 1/2 Trial of TG-1101 (ublituximab) monotherapy has been published in the British Journal of Haematology. This trial was studying the effect of ublituximab on patients with B-cell non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) that were previously exposed to rituximab. Ublituximab is an anti-CD20 monoclonal antibody.
Having another antibody in the arsenal of therapeutic options for CLL patients is good news. The other good news is that no dose limiting toxicities were identified in this trial.
Ublituximab seems to be effective even for some patients whose cancer has grown through Rituximab. Although this trial only included 8 patients with CLL, with only 6 that were able to be evaluated, 50% of those patients had a partial response and 50% had stable disease. These small numbers are not uncommon for Phase I trials. We look forward to seeing more data showing it’s efficacy in CLL. Additional CLL studies with ublituximab are being performed in combination with lenalidomide, ibrutinib, and TG-1202 with or without ibrutinib or bendamustine.
Read more here: